Chalmer, Thor Ameri
,
Kalincik, Tomas
Laursen, Bjarne
Sorensen, Per Soelberg
Magyari, Melinda
Funding for this research was provided by:
Scleroseforeningen
Foundation for Research in Neurology
Gangstedfonden
Direktør Ejnar Jonasson Kaldet Johnsen og Hustrus Mindelegat
Article History
Received: 18 September 2018
Revised: 8 November 2018
Accepted: 13 November 2018
First Online: 4 December 2018
Compliance with ethical standards
:
: TC has received support for congress participation from Merck, Novartis, Biogen and Roche. TK served on scientific advisory boards for Roche, Genzyme-Sanofi, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen. BL has nothing to disclose. PS has received personal compensation for serving on advisory boards for Biogen, Merck, Novartis, Teva, MedDay Pharmaceuticals and GSK; on steering committees or independent data monitoring boards in trials sponsored by Merck, Teva, GSK, and Novartis; and has received speaker honoraria from Biogen, Merck Serono, Teva, Sanofi-Aventis, Genzyme, and Novartis. MM has served on scientific advisory board for Biogen Idec, Novartis, Merck, Sanofi and Teva; has received honoraria for lecturing from Biogen Idec, Merck, Novartis and Genzyme; has received support for congress participation from Biogen Idec, Novartis, Genzyme and Teva.